Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has 4 years of EBITDA Margin data on record, last reported at 440356600.0% in Q4 2023.

  • On a quarterly basis, EBITDA Margin fell 44034978036.0% to 440356600.0% in Q4 2023 year-over-year; TTM through Sep 2024 was 2006393700.0%, a 200638765523.0% decrease, with the full-year FY2023 number at 7711.98%, up 697419.0% from a year prior.
  • EBITDA Margin reached 440356600.0% in Q4 2023 per IKT's latest filing, down from 5773.14% in the prior quarter.
  • Over the last five years, EBITDA Margin for IKT hit a ceiling of 186.56% in Q1 2021 and a floor of 440356600.0% in Q4 2023.
  • A 4-year average of 27549232.05% and a median of 5440.26% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 25251477bps in 2022, then crashed 2000000000bps in 2023.
  • Tracing IKT's EBITDA Margin over 4 years: stood at 704.66% in 2020, then plummeted by -36703bps to 259334.41% in 2021, then surged by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Business Quant data shows EBITDA Margin for IKT at 440356600.0% in Q4 2023, 5773.14% in Q3 2023, and 5107.38% in Q2 2023.